Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62018TA0059

    Case T-59/18: Judgment of the General Court of 22 November 2018 — Endoceutics v EUIPO — Merck (FEMIVIA) (EU trade mark — Opposition proceedings — Application for EU word mark FEMIVIA — Earlier EU word mark FEMIBION INTIMA — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)

    IO C 44, 4.2.2019, p. 46–46 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    4.2.2019   

    EN

    Official Journal of the European Union

    C 44/46


    Judgment of the General Court of 22 November 2018 — Endoceutics v EUIPO — Merck (FEMIVIA)

    (Case T-59/18) (1)

    ((EU trade mark - Opposition proceedings - Application for EU word mark FEMIVIA - Earlier EU word mark FEMIBION INTIMA - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001))

    (2019/C 44/58)

    Language of the case: English

    Parties

    Applicant: Endoceutics, Inc. (Quebec, Canada) (represented by: M. Wahlin, lawyer)

    Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė, acting as Agent)

    Other party to the proceedings before the Board of Appeal of EUIPO: Merck KGaA (Darmstadt, Germany)

    Re:

    Action brought against the decision of the Second Board of Appeal of EUIPO of 27 November 2017 (Case R 280/2017-2), relating to opposition proceedings between Merck and Endoceutics.

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Endoceutics, Inc. to pay the costs.


    (1)  OJ C 112, 26.3.2018.


    Top